Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: hpgrant who wrote (10273)	5/15/2018 12:23:31 PM
From: HardToFind	Read Replies (1) \| Respond to of 12873

Dr. Seymour has stated that he was resigning for personal reasons and to make room for a pharmaceutical industry executive with experience in drug development through regulatory stages. Sort of sounds like a non-denial denial. Yes, he did state that. It doesn't exactly explain why the $10K expense reimbursement (legal expenses?). It doesn't explain why Seymour was immediately removed from the BOD upon his resigning from his full-time position and moving to an emeritus role. It still seems unusual for options to be granted that vest after Seymour having left the company, as well as his salary coming in bimonthly instead of a lump sum upon departure. Perhaps the non-disparagement clause goes both ways.

To: hpgrant who wrote (10273)	5/15/2018 12:28:30 PM
From: HardToFind	Read Replies (2) \| Respond to of 12873

Executive Search Committee reports that it is now in due diligence phase Without coming right out and saying so, this seems to imply the company has either picked a lead candidate for replacing Seymour (which it is vetting), and/or have a small pool of lead candidates that are being vetted. I wonder how long that vetting process takes?

To: hpgrant who wrote (10273)	5/15/2018 2:42:06 PM
From: NanoPenguin	2 Recommendations Recommended By Another_Voice_2 mattstat Read Replies (1) \| Respond to of 12873

Dear Dr. Diwan, NanoViricides reports that it does not know of the reasons for a recent sharp decline in its stock price. The Company's current drug candidates in the HerpeCide™ program are moving towards the clinical stage steadily. The Company is diligently working towards obtaining all the information that we will need for filing our first Investigational New Drug application (IND). I am your long term faithful investor since 2005 (EDOT.com days). A lot of capital has been lost by shareholders that were supporting your dreams for years. I was surprised that you do not know why the stock price is going down. I was led to believe by you at the shareholder's meeting and other communications that the shinglescide candidate was moving forward right after the pre-tox was done. You mention nothing about the status of this in your 'update' PR. There is not even a pre-IND meeting set up as promised. I have no clue as to what the company is really doing since none of the plans never seem to come through. Your update does not even mention shinglescide. You told us all that this is the lead candidate. If that is no longer true, the shareholders should know. How can you not know why the stock price is going down? Also, I was led to believe that the licensing of shinglescide to NNVC was a mere formality and was being worked on and nothing ever happened. This should have been done already without question or the shareholders told what the problem is. Not promptly licensing shinglescide to NNVC causes distrust. The vague, misleading communications are unfair to us shareholders. I think the best thing this company can do is to vastly improve its communication to be open, honest and transparent.